ESMO 2022 Conference Coverage
Lecture Summary - ESMO 2022 on a Randomized Phase II METEORA-II Trial: Metronomic Oral Vinorelbine + Cyclophosphamide & Capecitabine vs. Weekly Paclitaxel as 1L/2L Treatment for ER+/HER2- mBC
By
ESMO 2022 Conference Coverage
FEATURING
Elisabetta Munzone
By
ESMO 2022 Conference Coverage
FEATURING
Elisabetta Munzone
Login to view comments.
Click here to Login
Breast